{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:57:13Z","timestamp":1790351833631,"version":"4.1.0"},"reference-count":5,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pure red cell aplasia (PRCA) is an uncommon complication secondary to ABO mismatched allogeneic stem\u2010cell transplantation (allo\u2010HSCT). The best approach for PRCA after allo\u2010HSCT remains unclear. We aim to report a single case with refractory PRCA post\u2010ABO mismatched allo\u2010HSCT resolved with daratumumab. A 34\u2010year\u2010old male diagnosed with aplastic anemia in March 2014 received a peripheral blood reduced\u2010intensity allo\u2010HSCT from an HLA\u2010matched related donor in July 2016. Donor and recipient blood groups were AB positive and 0 positive, respectively, indicating a major ABO incompatibility. The patient was diagnosed with PRCA 2\u00a0months after allo\u2010HSCT. After failing multiple standard lines of treatment, compassionate treatment with daratumumab was requested. After receiving six doses of daratumumab, the patient had a marked reticulocyte response and consecutively become transfusion independent. In conclusion, Daratumumab is a human IgG1\u03ba monoclonal antibody targeting CD38 and is used to treat multiple myeloma. The use of anti\u2010CD38 therapy with daratumumab to target residual host plasma cells is safe and effective, and it can be considered in refractory recipients with PRCA after allo\u2010HSCT secondary to ABO incompatibility.<\/jats:p>","DOI":"10.1111\/ejh.13343","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T16:16:40Z","timestamp":1573057000000},"page":"145-147","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab"],"prefix":"10.1111","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-3682","authenticated-orcid":false,"given":"Maria Queralt","family":"Salas","sequence":"first","affiliation":[{"name":"Section of Medical Oncology and Hematology Department of Medicine University of Toronto Toronto ON Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program Division of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alahmari","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology and Hematology Department of Medicine University of Toronto Toronto ON Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program Division of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Howard","family":"Lipton","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology and Hematology Department of Medicine University of Toronto Toronto ON Canada"},{"name":"Hans Messner Allogeneic Blood and Marrow Transplantation Program Division of Medical Oncology and Hematology Princess Margaret Cancer Centre University Health Network Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1687"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21553"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12121"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807438"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25515"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13343","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T09:20:16Z","timestamp":1694164816000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/ejh.13343"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13343","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"2019-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}